223 related articles for article (PubMed ID: 31740764)
21. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).
Heerding DA; Chan G; DeWolf WE; Fosberry AP; Janson CA; Jaworski DD; McManus E; Miller WH; Moore TD; Payne DJ; Qiu X; Rittenhouse SF; Slater-Radosti C; Smith W; Takata DT; Vaidya KS; Yuan CC; Huffman WF
Bioorg Med Chem Lett; 2001 Aug; 11(16):2061-5. PubMed ID: 11514139
[TBL] [Abstract][Full Text] [Related]
22. CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
Park HS; Yoon YM; Jung SJ; Yun IN; Kim CM; Kim JM; Kwak JH
Int J Antimicrob Agents; 2007 Nov; 30(5):446-51. PubMed ID: 17723291
[TBL] [Abstract][Full Text] [Related]
23. The food-grade antimicrobial xanthorrhizol targets the enoyl-ACP reductase (FabI) in Escherichia coli.
Yogiara ; Mordukhova EA; Kim D; Kim WG; Hwang JK; Pan JG
Bioorg Med Chem Lett; 2020 Dec; 30(24):127651. PubMed ID: 33130290
[TBL] [Abstract][Full Text] [Related]
24. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
Zhou P; Hong J
Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
[TBL] [Abstract][Full Text] [Related]
25. Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors.
Takhi M; Sreenivas K; Reddy CK; Munikumar M; Praveena K; Sudheer P; Rao BN; Ramakanth G; Sivaranjani J; Mulik S; Reddy YR; Narasimha Rao K; Pallavi R; Lakshminarasimhan A; Panigrahi SK; Antony T; Abdullah I; Lee YK; Ramachandra M; Yusof R; Rahman NA; Subramanya H
Eur J Med Chem; 2014 Sep; 84():382-94. PubMed ID: 25036796
[TBL] [Abstract][Full Text] [Related]
26. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.
Kitagawa H; Ozawa T; Takahata S; Iida M; Saito J; Yamada M
J Med Chem; 2007 Sep; 50(19):4710-20. PubMed ID: 17713898
[TBL] [Abstract][Full Text] [Related]
27. Virtual screening of antibacterial compounds by similarity search of Enoyl-ACP reductase (FabI) inhibitors.
Asse Junior LR; Kronenberger T; Magalhães Serafim MS; Sousa YV; Franco ID; Valli M; Silva Bolzani VD; Monteiro GC; Bruno Prates JL; Kroon EG; Fernandes Mota BE; Santos Ferreira DD; de Oliveira RB; Maltarollo VG
Future Med Chem; 2020 Jan; 12(1):51-68. PubMed ID: 31729258
[No Abstract] [Full Text] [Related]
28. Bone and Joint Tissue Penetration of the
Menetrey A; Janin A; Pullman J; Overcash JS; Haouala A; Leylavergne F; Turbe L; Wittke F; Nicolas-Métral V
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559136
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching.
Hevener KE; Mehboob S; Su PC; Truong K; Boci T; Deng J; Ghassemi M; Cook JL; Johnson ME
J Med Chem; 2012 Jan; 55(1):268-79. PubMed ID: 22098466
[TBL] [Abstract][Full Text] [Related]
30. Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.
Ozawa T; Kitagawa H; Yamamoto Y; Takahata S; Iida M; Osaki Y; Yamada K
Bioorg Med Chem; 2007 Dec; 15(23):7325-36. PubMed ID: 17892940
[TBL] [Abstract][Full Text] [Related]
31. Advances and challenges in bacterial compound accumulation assays for drug discovery.
Six DA; Krucker T; Leeds JA
Curr Opin Chem Biol; 2018 Jun; 44():9-15. PubMed ID: 29803973
[TBL] [Abstract][Full Text] [Related]
32. Predictive compound accumulation rules yield a broad-spectrum antibiotic.
Richter MF; Drown BS; Riley AP; Garcia A; Shirai T; Svec RL; Hergenrother PJ
Nature; 2017 May; 545(7654):299-304. PubMed ID: 28489819
[TBL] [Abstract][Full Text] [Related]
33. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.
Kronenberger T; Asse LR; Wrenger C; Trossini GH; Honorio KM; Maltarollo VG
Future Med Chem; 2017 Feb; 9(2):135-151. PubMed ID: 28128024
[TBL] [Abstract][Full Text] [Related]
34. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
Miller WH; Seefeld MA; Newlander KA; Uzinskas IN; Burgess WJ; Heerding DA; Yuan CC; Head MS; Payne DJ; Rittenhouse SF; Moore TD; Pearson SC; Berry V; DeWolf WE; Keller PM; Polizzi BJ; Qiu X; Janson CA; Huffman WF
J Med Chem; 2002 Jul; 45(15):3246-56. PubMed ID: 12109908
[TBL] [Abstract][Full Text] [Related]
35. Structure-based discovery of LpxC inhibitors.
Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
[TBL] [Abstract][Full Text] [Related]
36. From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
Gerusz V; Denis A; Faivre F; Bonvin Y; Oxoby M; Briet S; LeFralliec G; Oliveira C; Desroy N; Raymond C; Peltier L; Moreau F; Escaich S; Vongsouthi V; Floquet S; Drocourt E; Walton A; Prouvensier L; Saccomani M; Durant L; Genevard JM; Sam-Sambo V; Soulama-Mouze C
J Med Chem; 2012 Nov; 55(22):9914-28. PubMed ID: 23092194
[TBL] [Abstract][Full Text] [Related]
37. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
[TBL] [Abstract][Full Text] [Related]
38. AG205, a novel agent directed against FabK of Streptococcus pneumoniae.
Takahata S; Iida M; Osaki Y; Saito J; Kitagawa H; Ozawa T; Yoshida T; Hoshiko S
Antimicrob Agents Chemother; 2006 Aug; 50(8):2869-71. PubMed ID: 16870790
[TBL] [Abstract][Full Text] [Related]
39. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.
Corbett D; Wise A; Langley T; Skinner K; Trimby E; Birchall S; Dorali A; Sandiford S; Williams J; Warn P; Vaara M; Lister T
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533232
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria.
Hernandez V; Crépin T; Palencia A; Cusack S; Akama T; Baker SJ; Bu W; Feng L; Freund YR; Liu L; Meewan M; Mohan M; Mao W; Rock FL; Sexton H; Sheoran A; Zhang Y; Zhang YK; Zhou Y; Nieman JA; Anugula MR; Keramane el M; Savariraj K; Reddy DS; Sharma R; Subedi R; Singh R; O'Leary A; Simon NL; De Marsh PL; Mushtaq S; Warner M; Livermore DM; Alley MR; Plattner JJ
Antimicrob Agents Chemother; 2013 Mar; 57(3):1394-403. PubMed ID: 23295920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
